Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
-
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
-
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
-
Neurocrine Biosciences to Participate at Investor Conferences in September
-
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
-
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
-
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
-
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Trading Information
- Previous Close Price
- $111.88
- Day Range
- $112.18–114.18
- 52-Week Range
- $103.63–157.98
- Bid/Ask
- $111.00 / $113.82
- Market Cap
- $11.51 Bil
- Volume/Avg
- 784,263 / 909,203
Key Statistics
- Price/Earnings (Normalized)
- 18.93
- Price/Sales
- 5.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,500
- Website
- https://www.neurocrine.com
Competitors
Valuation
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.93 | 6.46 | 12.21 |
Price/Book Value | 4.50 | 3.10 | 1.92 |
Price/Sales | 5.42 | 1.20 | 2.72 |
Price/Cash Flow | 17.52 | 12.31 | 14.05 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Quick Ratio | 3.78 | 0.46 | 0.52 |
Current Ratio | 4.19 | 0.89 | 1.00 |
Interest Coverage | 4.18 | 0.83 | 8.61 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 19.61% | 7.18% | 7.59% |
Return on Equity (Normalized) | 27.66% | 43.52% | 14.17% |
Return on Invested Capital (Normalized) | 28.05% | 13.87% | 10.36% |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Lvpbxhbrqk | Rfqpc | $86.5 Bil | |||
| Merck KGaA ADR
MKKGY
| Wlzlcmtvg | Lqksck | $75.2 Bil | |||
| Haleon PLC ADR
HLN
| Jmwkvhzw | Wdwk | $46.6 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Swjkzyn | Ddpy | $19.9 Bil | |||
| Viatris Inc
VTRS
| Wkdymgr | Ldyq | $13.6 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Qtxbltm | Cpb | $13.4 Bil | |||
| Catalent Inc
CTLT
| Zwjgrtbtp | Hdlhrwj | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Vzxsbwz | Vljrqz | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Fyzfrrbz | Vzv | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Hjrbzfzk | Jmptj | $2.5 Bil |
United States